Icotrokinra Outperforms Deucravacitinib in Psoriasis Trials

Recent findings from the ICONIC-ADVANCE 1 and 2 trials demonstrate that icotrokinra (ICO) shows superior efficacy compared to deucravacitinib in treating psoriasis. The trials, which evaluated treatment responses at both 16 and 24 weeks, indicate that ICO not only outperforms its counterpart but also maintains a favorable safety profile. This development is particularly significant, as it highlights ongoing gaps in psoriasis care despite the increasing availability of therapeutic options.

At a recent Peer Exchange, Dr. Linda Stein Gold and her colleagues examined insights from the ENCOMPASS and Stein Gold 2025 surveys. Their analysis revealed that many patients remain dissatisfied with existing therapies, with a strong preference for oral agents over injectable treatments. This dissatisfaction is largely influenced by factors such as patient lifestyle, comorbidities, and the psychosocial burden associated with psoriasis.

The panel also discussed the International Psoriasis Council’s (IPC) new definition of “topical failure,” emphasizing its importance in guiding treatment decisions. They explored how this definition could reduce “topical churn,” encouraging earlier transitions to systemic therapies when needed.

Investigational Pipeline and Clinical Insights

The discussion shifted to the investigational drug pipeline, with a detailed review of ICO’s clinical development program. The ICONIC-ADVANCE trials demonstrated not only superior efficacy but also the potential for sustained clearance, as indicated by new data from the week 52 ICONIC-LEAD study. This study revealed no new safety signals among adult and adolescent participants, suggesting a robust profile for ICO as a treatment option.

Dr. Stein Gold and her team reflected on the implications of ICO for treating adolescent psoriasis. They noted that early and aggressive oral interventions could play a crucial role in preventing the progression to psoriatic arthritis (PsA), marking a pivotal advancement in oral IL-23–targeted therapies.

Advancing Psoriatic Arthritis Management

The final segment of the series focused on managing active psoriatic arthritis, highlighting findings from the APEX phase 3b study. This research demonstrated that guselkumab provides clear evidence of IL-23–mediated inhibition of structural joint damage. This milestone reinforces the rationale for early biologic intervention in high-risk patients, offering new hope for effective disease management.

The experts compared the APEX study results with previous IL-23 trials, discussing implications for therapy sequencing. They also highlighted emerging data from the upcoming Fall Clinical 2025 conference, including the SPECTREM and PSOLAR studies, which are expected to provide further insights into treatment strategies.

In conclusion, Dr. Stein Gold and her colleagues advocate for a forward-looking approach that emphasizes personalized therapy selection, early detection of PsA, and enhanced collaboration across specialties. This integrated approach aims to elevate the standards of psoriasis care and better meet the needs of patients facing this chronic condition.